| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA816: Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer |
|
Medicine details |
|
| Medicine name | alpelisib (Piqray®) |
| Formulation | 50 mg, 150 mg , 200 mg film-coated tablet |
| Reference number | 3088 |
| Indication | In combination with fulvestrant for the treatment of postmenopausal women , and men, with hormone receptor (HR)-positive , human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 10/06/2020 |
| NICE guidance | |